Targeting Beta-Amyloid and Tau in Alzheimer's Research

A

Alfred Sandrock, Chief Medical Officer at Biogen, during the Milken Institute panel discussion.

Mental HealthMedical

Quotes From Source

In Alzheimer's disease, there's buildup of proteins in the brain...

Story of claim

Alfred Sandrock highlights the current focus of most companies on targeting beta-amyloid and tau proteins for Alzheimer's treatment. These proteins are toxic when misfolded, damaging neurons.

  • Goal: Develop treatments that target beta-amyloid and tau pathways to combat Alzheimer's disease.
  • Proof: Targeting beta-amyloid and tau can potentially reduce neuronal damage caused by protein build-up, as companies are in phase 3 clinical trials.
  • Nuances:
    • Beta-amyloid and tau are toxic when misfolded
    • Clinical trials targeting these pathways are in phase 3
  • Impact on Life: Potential to improve life quality for Alzheimer's patients through reduced neuronal damage, possibly slowing disease progression.

Investments

  • Price: Not directly stated, but high due to clinical trials and research.
  • Time: Several years for clinical trials and drug development.
  • Effort: High effort in R&D and maintaining long-term trials.

Risks

Clinical trials may not yield successful treatment outcomes; potential side effects of new treatments are unknown.

Alternatives

  • Lifestyle changes: focusing on diet, exercise, and mental health to manage symptoms
  • Existing Alzheimer's medications for symptom management

Get Started 🚀

  • Stay informed about clinical trial results and new research
  • Consider participating in clinical trials if eligible
  • Consult healthcare providers about emerging treatments

Brogevity AI can make mistakes. Check important info.


Reference Video